Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug Delivery System

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777585

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777585

Sterile Injectable Contract Manufacturing

PUBLISHED:
PAGES: 387 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Sterile Injectable Contract Manufacturing Market to Reach US$28.7 Billion by 2030

The global market for Sterile Injectable Contract Manufacturing estimated at US$15.5 Billion in the year 2024, is expected to reach US$28.7 Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2024-2030. Small Molecule, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$16.9 Billion by the end of the analysis period. Growth in the Large Molecule segment is estimated at 13.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.2 Billion While China is Forecast to Grow at 14.4% CAGR

The Sterile Injectable Contract Manufacturing market in the U.S. is estimated at US$4.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 9.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Sterile Injectable Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Contract Manufacturing of Sterile Injectables Becoming a Cornerstone of the Biopharma Supply Chain?

Sterile injectable contract manufacturing is increasingly central to the pharmaceutical and biotech industries, driven by the complexity, cost, and regulatory rigor associated with producing injectable drugs in sterile environments. As demand for injectable formulations rises-spanning biologics, vaccines, monoclonal antibodies, oncology drugs, and emergency care therapeutics-drug developers are outsourcing manufacturing to specialized CDMOs (Contract Development and Manufacturing Organizations) that offer the infrastructure, technical expertise, and compliance credentials necessary for sterile production. The need to maintain aseptic conditions, mitigate contamination risks, and adhere to stringent FDA, EMA, and WHO guidelines has made in-house production both risky and resource-intensive, especially for emerging biotech firms and specialty pharma companies. Moreover, sterile injectables often require high containment technologies, fill-finish services, and lyophilization capabilities that only a select group of contract manufacturers can deliver efficiently. As speed-to-market and production scalability become competitive differentiators in the post-pandemic era, outsourcing sterile injectables has become a strategic imperative, not just a cost-saving measure-especially in the race to commercialize life-saving therapies and respond to global health emergencies.

How Are Technological Advancements and Regulatory Compliance Shaping Service Offerings?

The sterile injectable contract manufacturing market is being rapidly transformed by the adoption of advanced aseptic processing technologies, digitized manufacturing operations, and global harmonization of quality standards. State-of-the-art cleanroom designs, isolator and RABS (Restricted Access Barrier Systems) technology, and automated filling lines are enabling CDMOs to produce high-purity injectables with reduced contamination risks and improved batch consistency. Single-use technologies are increasingly being integrated into upstream and downstream workflows to minimize cross-contamination, reduce downtime, and increase flexibility-especially for multi-product facilities. Many contract manufacturers are investing in high-speed, multi-format filling lines that accommodate vials, prefilled syringes, ampoules, and cartridges, enabling greater versatility in handling customer demand. Digitalization through MES (Manufacturing Execution Systems), eBatch records, and real-time monitoring platforms is improving traceability, regulatory compliance, and audit readiness. CDMOs are also adapting to evolving global regulatory frameworks, achieving certifications such as cGMP, PIC/S, and ISO, which are increasingly required for cross-border commercialization. The ability to offer end-to-end solutions-including formulation, aseptic fill-finish, lyophilization, packaging, labeling, and serialization-is now a major value proposition for CDMOs looking to differentiate in a highly competitive and regulation-heavy environment.

Where Is Demand Surging, and Which Therapeutic Areas Are Fueling Market Expansion?

The demand for sterile injectable contract manufacturing is surging across both developed and emerging markets, with North America and Europe leading in terms of CDMO capacity and innovation, while Asia-Pacific is rapidly gaining prominence due to cost efficiency and growing regulatory alignment. The U.S. remains the largest market, driven by a strong biotech ecosystem, advanced biologics development, and high outsourcing rates among small and mid-sized pharma companies. Europe follows closely, with countries like Germany, Switzerland, and Ireland hosting specialized facilities that serve global clientele. In Asia, India and China are expanding their sterile injectable infrastructure, drawing increased interest from multinational pharmaceutical companies seeking capacity, affordability, and regulatory-compliant production. Therapeutically, oncology leads the demand due to the prevalence of injectable chemotherapy and immunotherapy drugs. Infectious diseases, including vaccines and antibiotics, are also major growth drivers, especially in light of global preparedness for pandemics and antimicrobial resistance. Other high-demand segments include diabetes (injectable insulin and GLP-1 agonists), autoimmune diseases, and central nervous system disorders. Biologics and biosimilars, many of which require parenteral delivery, are further fueling demand, as drug pipelines become increasingly weighted toward complex molecules that require specialized sterile manufacturing solutions.

What’s Driving the Long-term Growth of the Sterile Injectable Contract Manufacturing Market Globally?

The growth in the sterile injectable contract manufacturing market is driven by a convergence of biopharma innovation, operational complexity, regulatory evolution, and global healthcare dynamics. A fundamental long-term driver is the proliferation of injectable biologics and advanced therapies, which require high-precision aseptic processes and highly controlled environments that are challenging to replicate in-house. As drug development pipelines shift toward niche and high-value therapeutics, companies are increasingly turning to CDMOs to access specialized capabilities without the burden of capital investment. Additionally, the growing prevalence of chronic and age-related diseases is fueling long-term demand for injectable treatments that offer rapid bioavailability and sustained efficacy. Regulatory authorities worldwide are mandating higher levels of sterility assurance, serialization, and data integrity-creating barriers to entry that CDMOs are uniquely positioned to overcome. Rising demand for rapid response capabilities, as seen during the COVID-19 pandemic, is pushing pharmaceutical companies to secure flexible, scalable partnerships for fill-finish and vaccine production. Furthermore, global drug shortages and the need for supply chain resilience are prompting companies to diversify manufacturing footprints, often through external partnerships. As the industry continues to prioritize speed, safety, and scalability in injectable therapeutics, sterile injectable contract manufacturing will remain a key strategic lever-supporting innovation, access, and sustainability in global drug development.

SCOPE OF STUDY:

The report analyzes the Sterile Injectable Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Molecule Type (Small Molecule, Large Molecule); Therapeutic Area (Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal, Anti-viral, Others); End-Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Contract Manufacturing
  • Aenova Group
  • Ajinomoto Bio-Pharma Services
  • Alcami Corporation
  • Baxter BioPharma Solutions
  • Baxter International Inc.
  • Bespak (Consort Medical)
  • Boehringer Ingelheim
  • Catalent, Inc.
  • Cipla Inc.
  • CordenPharma
  • Delpharm
  • Eurofins CDMO
  • Famar Health Care Services
  • Fresenius Kabi AG
  • Grifols S.A.
  • Hikma Pharmaceuticals plc
  • Jubilant HollisterStier
  • Lonza Group
  • NextPharma Technologies
  • Patheon (Thermo Fisher)
  • Pfizer CentreOne
  • Recipharm AB
  • Samsung Biologics
  • Sandoz International GmbH
  • Siegfried Holding AG
  • Thermo Fisher Scientific
  • Unither Pharmaceuticals
  • Vetter Pharma
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP33055

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Sterile Injectable Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Outsourcing of Complex Biologics Throws the Spotlight on Sterile Injectable Contract Manufacturing as a Strategic Pillar
    • Surging Demand for Biologics, Biosimilars, and mRNA Therapies Spurs Capacity Expansion in Sterile Fill-finish Services
    • Here's How the Shift Toward Injectable Drug Delivery Expands the Addressable Market for Aseptic Manufacturing Partners
    • Increased Complexity of Drug Formulations Strengthens the Business Case for Specialist CDMOs with Sterile Injectable Expertise
    • Here's the Story: Pre-filled Syringes, Vials, and Cartridges Drive Demand for Flexible, Multi-format Injectable Fill Lines
    • Rising Regulatory Scrutiny and GMP Compliance Requirements Propel Investment in Quality-centric Manufacturing Facilities
    • Growth in Orphan Drugs and Fast-track Therapies Fuels Need for Agile, Small-batch Sterile Injectable Manufacturing Capabilities
    • Emergence of Lyophilized and Temperature-sensitive Injectables Unlocks Demand for Niche Sterile Processing Technologies
    • Here's How Drug Shortages and Lifecycle Extension Strategies Create Opportunities in Generic Injectable Contract Manufacturing
    • Expansion of Biopharma in Emerging Markets Drives Globalization of Sterile Injectable Manufacturing Footprint
    • Innovations in Isolator Technology and Closed-system Processing Enhance Sterility Assurance and Worker Safety
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sterile Injectable Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sterile Injectable Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Sterile Injectable Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Small Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Large Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Central Nervous System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Central Nervous System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Central Nervous System Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Infectious Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Infectious Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Infectious Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Musculoskeletal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Musculoskeletal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Musculoskeletal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Anti-viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Anti-viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Anti-viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Sterile Injectable Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Sterile Injectable Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Sterile Injectable Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Sterile Injectable Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Sterile Injectable Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Sterile Injectable Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Sterile Injectable Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Sterile Injectable Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Sterile Injectable Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Sterile Injectable Contract Manufacturing by Molecule Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Sterile Injectable Contract Manufacturing by Molecule Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Sterile Injectable Contract Manufacturing by Therapeutic Area - Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Sterile Injectable Contract Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Cancer, Diabetes, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal and Anti-viral for the Years 2015, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Sterile Injectable Contract Manufacturing by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Sterile Injectable Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!